89bio, Inc. (ETNB)
After hours:
| Previous close | 9.37 |
| Open | 9.44 |
| Bid | 9.15 x 200 |
| Ask | 9.21 x 100 |
| Day's range | 9.11 - 9.57 |
| 52-week range | 6.57 - 22.93 |
| Volume | |
| Avg. volume | 1,291,670 |
| Market cap | 856.471M |
| Beta (5Y monthly) | 0.95 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -2.00 |
| Earnings date | 02 May 2024 - 06 May 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 31.89 |
GlobeNewswire89bio Appoints Biotech Industry Veteran, Martin Babler to its Board of Directors
SAN FRANCISCO, April 17, 2024 (GLOBE NEWSWIRE) -- 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardiometabolic diseases, today announced the appointment of Martin Babler to its Board of Directors, effective April 13, 2024. Mr. Babler, a highly successful executive who brings valuable industry experience to 89bio, currently serves as President, Chief Executive Officer
- GlobeNewswire
89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SAN FRANCISCO, April 05, 2024 (GLOBE NEWSWIRE) -- 89bio, Inc. (the “Company” or “89bio”) (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardiometabolic diseases, today announced that the Compensation Committee of the Company’s Board of Directors approved the grant of non-qualified stock options to purchase an aggregate of 138,550 shares of the Company’s common stock to eight new em
GuruFocus.com89bio Inc CEO Rohan Palekar Sells 52,718 Shares
Rohan Palekar, CEO of 89bio Inc (NASDAQ:ETNB), executed a sale of 52,718 shares in the company on April 1, 2024, according to a recent SEC Filing.
